Indeed short-term, systemic delivery of CU-3, a selective inhibitor of DGKα-mediated PA biosynthesis, reduced MQ infiltration, inflammation, and MMP activity during the acute phase and mitigated LV remodeling during the chronic phase in MI. The gene discussed is DGKA; the disease is myocardial infarction.